Mpho Phehello Ngoepe

Mpho Phehello Ngoepe

Auto-generated profile, based on publicly available information

Mpho Phehello Ngoepe

DSI‐Mandela Nanomedicine Platform Nelson Mandela University Gqeberha Eastern Cape South Africa

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2013 in Sensors
Verified
Journal Article
Open access
PDF file
MNMpho Ngoepe
Mpho Ngoepe
Yahya ChoonaraYahya Choonara
Yahya Choonara
CTCharu Tyagi
Charu Tyagi
LTLomas Tomar
Lomas Tomar
LTLisa du Toit
Lisa du Toit
VPViness Pillay
Viness Pillay
Recent advances in biosensor design and sensing efficacy need to be amalgamated with research in responsive drug delivery systems for building superior health or illness regimes and ensuring good patient compliance. A variety of illnesses require continuous monitoring in order to have efficient illness intervention. Physicochemical changes in the body can signify the occurrence of an illness before it manifests. Even with the usage of sensors that allow diagnosis and prognosis of the illness, medical intervention still has its downfalls. Late detection of illness can reduce the efficacy of therapeutics. Furthermore, the conventional modes of treatment can cause side-effects such as tissue damage (chemotherapy and rhabdomyolysis) and induce other forms of illness (hepatotoxicity). The use of drug delivery systems enables the lowering of side-effects with subsequent improvement in patient compliance. Chronic illnesses require continuous monitoring and medical intervention for efficient treatment to be achieved. Therefore, designing a responsive system that will reciprocate to the physicochemical changes may offer superior therapeutic activity. In this respect, integration of biosensors and drug delivery is a proficient approach and requires designing an implantable system that has a closed loop system. This offers regulation of the changes by means of releasing a therapeutic agent whenever illness biomarkers prevail. Proper selection of biomarkers is vital as this is key for diagnosis and a stimulation factor for responsive drug delivery. By detecting an illness before it manifests by means of biomarkers levels, therapeutic dosing would relate to the severity of such changes. In this review various biosensors and drug delivery systems are discussed in order to assess the challenges and future perspectives of integrating biosensors and drug delivery systems for detection and management of chronic illness.

25 July 2025 in Biotechnology Journal
Verified
Journal Article
Open access
MNMpho Phehello Ngoepe
Mpho Phehello Ngoepe
SSStiaan Schoeman
Stiaan Schoeman
SRSaartjie Roux
Saartjie Roux
The use of metal and metal oxide nanoparticles has been suggested as a means of combating antibiotic‐resistant bacteria (ARB). This is due to the ability of nanoparticles to target numerous sites inside the bacterial cell. Microbes can, however, develop a resistance to hazardous environments. Soil microorganisms have evolved resistance to specific metals in soil by employing alternative survival strategies, like those adopted against antibiotics. Because of this survival mechanism, bacteria have been able to develop defense mechanisms to deal with metallic nanoparticles. Resistance has evolved in human pathogens to therapies that use metallic nanoparticles, such as silver nanoparticles. Metallic nanoparticles and antibiotics have currently been proven to be ineffective against several infections. Due to these concerns, scientists are investigating whether nanoparticles might cause environmental harm and potentially breed microbes that are resistant to both inorganic and organic nanoparticles. The increased use of inorganic nanoparticles has thus been shown to result in contaminations in wastewater, facilitating horizontal gene transfer among bacterial populations. The resistance mechanism of metallic nanoparticles, role in antibiotic resistance, and a potential solution to the environment's toxicity from nanoparticles are all discussed in this review.

1 December 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
NONnamdi Ikemefuna Okafor
Nnamdi Ikemefuna Okafor
MNMpho Ngoepe
Mpho Ngoepe
XNXavier Siwe Noundou
Xavier Siwe Noundou
RKRui Werner Maçedo Krause
Rui Werner Maçedo Krause

1 January 2023 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MMMaluta Steven Mufamadi
Maluta Steven Mufamadi
MNMpho Phehello Ngoepe
Mpho Phehello Ngoepe
ONOfentse Nobela
Ofentse Nobela
NMNhlanhla Maluleke
Nhlanhla Maluleke
BPBafedile Phorah
Bafedile Phorah
LKLebogang Maureen Katata-Seru
Lebogang Maureen Katata-Seru
The virus responsible for the coronavirus viral pandemic is the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Emerging SARS‐CoV‐2 variants caused by distinctive mutations within the viral spike glycoprotein of SARS‐CoV‐2 are considered the cause for the rapid spread of the disease and make it challenging to treat SARS‐CoV‐2. The manufacturing of appropriate efficient vaccines and therapeutics is the only option to combat this pandemic. Nanomedicine has enabled the delivery of nucleic acids and protein‐based vaccines to antigen‐presenting cells to produce protective immunity against the coronavirus. Nucleic acid‐based vaccines, particularly mRNA nanotechnology vaccines, are the best prevention option against the SARS‐CoV‐2 pandemic worldwide, and they are effective against the novel coronavirus and its multiple variants. This review will report on progress made thus far with SARS‐CoV‐2 vaccines and beyond employing nanotechnology‐based nucleic acid vaccine approaches.


6 May 2024 in Trends in Biotechnology
Verified
Journal Article
Closed access
MKMkliwa Koumbia
Mkliwa Koumbia
MNMpho Ngoepe
Mpho Ngoepe
JHJoseph Benjamin Holman
Joseph Benjamin Holman
MMMaluta Steven Mufamadi
Maluta Steven Mufamadi
MTMadoka Takai
Madoka Takai